非酒精性脂肪性肝病的发病机制与研究现状
被引量:4
摘要
非酒精性脂肪性肝病(nonalcoholic fatty liver disease,NAFLD)是一种无过量饮酒史,由各种原因引起的干细胞内脂肪堆积,以肝细胞脂肪变性和脂质蓄积为主要特征的临床病理综合征。
出处
《河北医药》
CAS
2011年第10期1563-1564,共2页
Hebei Medical Journal
参考文献11
-
1Alter M J, Kruszzon D, Nainan DV, et al. The prevalence of hepatitis C virus infection in the united states, 1988 though 1994. N Engl J Med, 2008,341:556-562.
-
2Guha IN, Parkes J, Roderick P, et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology ,2008,47:455.460.
-
3Zamora-Valdes D, Mendez-Sanchez N. Experimental evidence of obstructive sleep apnea syndrome as a second hit accomplice in nonalcoholic steatohepatitis pathogenesis. Ann Hepatol,2007 ,6 :281-283.
-
4de Oliveira CP, de Mello ES, Alves VA, et al. Changes in histological criteria lead to different prevalenees of nonalcoholic steatohepatitis in severe obesity. Ann Hepatol,2007 ,6 :255-261.
-
5Duseja A, Thumburu KK, Das A, et al. Insulin tolerance test is comparable to homeostasis model assessment for insulin resistance in patients with nonalcoholic fatty liver disease. Indian J Gastroenterol, 2007,26: 170- 173.
-
6Marchesini G, Babini M. Nonalcoholic fatty liver disease and the metabolic syndrome. Minerva Cardioangiol,2006,54:229-239.
-
7Ahmed MH, Saad RA, Osman MM. Ezetimibe: effective and safe treatment for dyslipidaemia associated with nonalcoholic fatty liver disease. Response to : Toth PP, Davidson MH : simvastatin and ezetimibe: combination therapy for the management of dyslipidaemia. Expert Opin Pharmacother,2008,6 : 131-139.
-
8Yoneda M, Fujita K, Iwasaki T, et al. Treatment of NASH: nutritional counseling and physical exercise. Nippon Rinsho,2006,64 : 1139-1145.
-
9Harano Y, Yasui K, Toyama T, et al. Fenofibrate, a perexisome proliferatot-activated receptor alpha agonist, reduces hepatic steatosis and lipid perexidation in fatty liver Shionogi mice with hereditary fatty liver. Liver Int,2008,26:613-620.
-
10Badman MK, Pissios P, Kennedy AR, et al. Hepatic fiboblast grow factor 21 is regulated by PPARpha and is a key mdeiator of hepatic lipid matabolism in ketotic states. Cell Metab,2007,5:426-437.
同被引文献32
-
1陈巍,翁彭剑,高国生,颜华东,毛达峰,祝成亮.剪切波速与四种无创血清评分系统对慢性肝炎患者肝纤维化诊断效果的比较[J].中华临床感染病杂志,2013,6(5):269-272. 被引量:11
-
2范建高,朱军,李新建,李锐,戴菲,宋晓敏,陈兰,李锋,陈世耀.上海市成人脂肪肝患病率及其危险因素流行病学调查[J].中华肝脏病杂志,2005,13(2):83-88. 被引量:583
-
3陆维,陆新安,华嘉临.1317例脂肪肝流行病学分析及防治对策[J].江苏预防医学,2005,16(3):16-17. 被引量:10
-
4范建高,李锋,蔡晓波,沃千红,高燕.非酒精性脂肪性肝病导致代谢紊乱患病率增高的队列研究[J].中华内分泌代谢杂志,2007,23(1):28-29. 被引量:12
-
5王吉耀.脂肪肝临床流行病学[J].中华肝脏病杂志,2000,8(4):115-115.
-
6Coumane S,Browne JE,Fagan AJ. The effects of fatty deposits on the accuracy of the Fibroscan? liver transient elastography ultrasound sys-tem[J].Phys Med Biol,2012,57(12):3901-3914.
-
7Wang T,Jing Y. Transcranial ultrasound imaging with speed of sound-based phase correction: a numerical study [J]. Phys Med Biol,2013,58(19):6663-6681.
-
8刘京,彭忠田.ARFI、FibrcScan无创诊断肝纤维化的研究进展[J].健康必读(下旬刊),2013(9):578-544.
-
9Fontanarosa D,Pesente S,Pascoli F,et al. A speed of sound aberration correction algorithm for curvilinear ultrasound transducers in ultrasound-based image-guided radiotherapy[J]. Phys Med Biol,2013,58(5):1341-1360.
-
10吴汝桐,袁润强,王秀玲,张丽娜.中山市成人脂肪肝患病率及相关危险因素分析[J].海南医学,2008,19(8):162-163. 被引量:4
引证文献4
-
1曾远强,黄伟波,张燕辉.清远市体检人群脂肪肝病调查分析[J].中外医学研究,2013,11(22):88-90.
-
2商建红.脂肪肝患者对疾病相关知识的了解及需求调查分析[J].当代护士(下旬刊),2014,21(11):27-28. 被引量:2
-
3李卫东,夏金荣,连燕舒.非酒精性脂肪性肝病与新诊断2型糖尿病关系的病例对照研究[J].中国全科医学,2014,17(34):4075-4078. 被引量:5
-
4黄国庆,袁华琴,吴俊,高枫,徐洪恩.声速匹配组织量化技术定量评价非酒精性脂肪性肝病的初步研究[J].中华全科医学,2016,14(5):826-827.
二级引证文献7
-
1郑仲萍,田峰,郑志刚,张国庆,郭锋,郭杏花.二甲双胍联用六味地黄丸对T2DM并NAFLD患者血清病情相关分子含量的影响[J].海南医学院学报,2016,22(10):972-975. 被引量:16
-
2周丽荣,马艳.2型糖尿病合并非酒精性脂肪性肝病患者的胰岛功能变化[J].医学综述,2016,22(16):3263-3266. 被引量:5
-
3陈艳,王珍茹,张丽,贾嫄.单纯性脂肪肝患者认知行为现状调查及生活方式干预[J].齐鲁护理杂志,2018,24(13):78-81. 被引量:10
-
4王晖,高清华,张楚华,陶军秀.非酒精性脂肪性肝病患者生存质量调查分析[J].时珍国医国药,2018,29(8):1906-1908. 被引量:7
-
5张茹,王宏亮,张薇,王青青,钟玉玲,凡豪志,田亭,张留馨,王洁.南京市某功能社区人群非酒精性脂肪性肝病的知信行调查及其影响因素分析[J].现代预防医学,2019,46(24):4461-4466. 被引量:6
-
6张学峰,杨光旭,朱友,张丹丹,夏金荣,李卫东.NAFLD对大鼠葡萄糖、胰岛素代谢和肝糖原合成的影响[J].东南大学学报(医学版),2020,39(4):420-424. 被引量:4
-
7余琳颖.33例肝病合并2型糖尿病患者的临床治疗分析[J].世界最新医学信息文摘,2018,18(44):46-46. 被引量:1
-
1黄雷,陈宁,宋仁权.非酒精性脂肪肝患者血浆同型半胱氨酸水平变化及临床意义[J].现代实用医学,2017,29(3):334-336. 被引量:6
-
2邬月琴,王淑贤,金树琦,王云枝,张柱,乔庆红.非酒精性脂肪肝病与糖尿病冠状动脉病变的关系[J].临床荟萃,2010,25(20):1794-1795. 被引量:1
-
3李晓红,王瑶,董利平.2型糖尿病合并非酒精性脂肪肝患者的胰岛素、血脂及脂联素的变化[J].山东医药,2008,48(7):86-87. 被引量:4
-
4梅海云,尚文斌,时良玺.中医药治疗2型糖尿病合并非酒精性脂肪肝病研究进展[J].河北中医,2011,33(6):947-949.
-
5陈韶华,厉有名.过氧化物酶体增殖物激活受体(PPAR)α在非酒精性脂肪肝中的新视点:关注PPARα与肝癌[J].中华肝脏病杂志,2014,22(9):718-720. 被引量:1
-
6潘琳.温胆汤加减治疗非酒精性脂肪肝疗效观察[J].临床合理用药杂志,2013,6(13):92-93. 被引量:8
-
7宋建芳,程雪娟,王景全.非酒精性脂肪肝与2型糖尿病及视网膜病变的相关性研究[J].河北医药,2012,34(17):2626-2627. 被引量:1
-
8张雪玲,李建绪.罗格列酮治疗非酒精性脂肪性肝炎患者疗效观察[J].中国全科医学,2009,12(11):949-951. 被引量:1
-
9李晨芳,王颜刚.非酒精性脂肪肝患者性激素结合球蛋白的变化及意义[J].山东医药,2011,51(17):34-35. 被引量:1
-
10张云良,张润兰,李志红,王君,李红星,王海燕,周秀英.罗格列酮治疗2型糖尿病合并脂肪肝疗效观察[J].中国糖尿病杂志,2007,15(11):672-673. 被引量:2